STOCK TITAN
  1. Home
  2. Sec-filings
  3. NUVL
  4. [SCHEDULE 13G] Nuvalent, Inc. SEC Filing

[SCHEDULE 13G] Nuvalent, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock NUVL logo
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

#1244 Ranked by Market Cap
N/A Ranked by Dividends

NUVL Latest News

Sep 24, 2025
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
Sep 7, 2025
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
Aug 28, 2025
Nuvalent to Participate in the Cantor Global Healthcare Conference 2025
Aug 13, 2025
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium
Aug 7, 2025
Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

NUVL Latest SEC Filings

Sep 29, 2025
[144] Nuvalent, Inc. SEC Filing
Sep 29, 2025
[144] Nuvalent, Inc. SEC Filing
Sep 22, 2025
[8-K] Nuvalent, Inc. Reports Material Event
Sep 22, 2025
[8-K] Nuvalent, Inc. Reports Material Event
Sep 17, 2025
[Form 4] Nuvalent, Inc. Insider Trading Activity

NUVL Stock Data

6.12B
63.38M
2.84%
109.13%
7.61%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE